FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint
FKD Therapies Oy (FKD) has led the development and regulatory filing of nadofaragene firadenovec, which has been studied in 33 centers across the U.S. in collaboration with the